10573132.trn

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJHM1624

PASSWORD:
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 17:49:51 ON 19 SEP 2007
FILE 'CAPLUS' ENTERED AT 17:49:51 ON 19 SEP 2007
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	102.95	564.39

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-14.82	-28.08

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	103.42	564.86

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-14.82	-28.08

FILE 'REGISTRY' ENTERED AT 17:50:20 ON 19 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 18 SEP 2007 HIGHEST RN 947490-11-1
DICTIONARY FILE UPDATES: 18 SEP 2007 HIGHEST RN 947490-11-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10 series\10573132\10573132a.str





chain nodes :
10
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
7-10
ring bonds :
1-2 1-7 2-3 3-4 3-8 4-5 5-6 6-7 6-9 8-9
exact/norm bonds :
1-2 1-7 2-3 3-4 3-8 4-5 5-6 6-7 6-9 8-9
exact bonds :
7-10

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS

L10 STRUCTURE UPLOADED

=> d l10
L10 HAS NO ANSWERS
L10 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l10
SAMPLE SEARCH INITIATED 17:50:42 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 3760 TO ITERATE

```
 53.2% PROCESSED     2000 ITERATIONS                                2 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        71523 TO    78877
PROJECTED ANSWERS:               2 TO      191

L11           2 SEA SSS SAM L10

=> d scan
```

L11 2 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4-Aza-1-azoniabicyclo[3.2.2]nonane, 4-hexyl-6-(hydroxyimino)-3-oxo-1-[[4-[[[3-oxo-3-(2-propenyloxy)propyl]amino]carbonyl]phenyl]methyl]-, salt with
trifluoroacetic acid (1:1) (9CI)
MF C27 H39 N4 O5 . C2 F3 O2

CM 1



CM 2

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

10573132.trn

=>
Uploading C:\Program Files\Stnexp\Queries\10 series\10573132\10573132b.str





chain nodes :
10
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
7-10
ring bonds :
1-2 1-7 2-3 3-4 3-8 4-5 5-6 6-7 6-9 8-9
exact/norm bonds :
1-2 1-7 2-3 3-4 3-8 4-5 5-6 6-7 6-9 8-9
exact bonds :
7-10

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS

L12 STRUCTURE UPLOADED

=> d l12
L12 HAS NO ANSWERS
L12 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l12

```
SAMPLE SEARCH INITIATED 17:51:59 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     3760 TO ITERATE

 53.2% PROCESSED     2000 ITERATIONS                                 1 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        71523 TO    78877
PROJECTED ANSWERS:               1 TO      119

L13           1 SEA SSS SAM L12

=> d scan
```

L13 1 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1,4-Diazabicyclo[3.2.2]nonane,
4-[[4'-(5-methyl-1,2,4-oxadiazol-3-yl)[1,1'-
biphenyl]-4-yl]methyl]-
MF C23 H26 N4 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

```
=> s l12 full
FULL SEARCH INITIATED 17:52:15 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    76206 TO ITERATE

100.0% PROCESSED    76206 ITERATIONS                                65 ANSWERS
SEARCH TIME: 00.00.02

L14          65 SEA SSS FUL L12

=> d scan
```

L14 65 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1,4-Diazabicyclo[3.2.2]nonane, 4-[(5-bromo-2-thienyl)methyl]- (9CI)
MF C12 H17 Br N2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L14 65 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1,4-Diazabicyclo[3.2.2]nonane, 4-[(5-phenyl-2-thienyl)methyl]- (9CI)
MF C18 H22 N2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

```
=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     173.45     738.31

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00     -28.08

FILE 'CAPLUS' ENTERED AT 17:52:33 ON 19 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 19 Sep 2007  VOL 147 ISS 13
FILE LAST UPDATED: 18 Sep 2007  (20070918/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l14
L15          9 L14

=> d l15 1-9 ibib abs hitstr
```

L15 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:76714 CAPLUS
DOCUMENT NUMBER: 144:150370
TITLE: [1,2,4]Oxadiazol-3-ylbiphenylmethylamines as histamine-3 receptor antagonists and their preparation, pharmaceutical compositions, and use in the treatment of disorders or conditions that may be treated by antagonizing histamine-3 receptors
INVENTOR(S): Wager, Travis T.; Howard, Harry R.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 23 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006019998	A1	20060126	US 2005-180185	20050713
CA 2573920	A1	20060202	CA 2005-2573920	20050711
WO 2006011043	A1	20060202	WO 2005-IB2186	20050711
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1771449	A1	20070411	EP 2005-759132	20050711
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				

PRIORITY APPLN. INFO.: US 2004-589893P P 20040721
WO 2005-IB2186 W 20050711

OTHER SOURCE(S): MARPAT 144:150370
GI



L15 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



I



II

AB This invention is directed to a class of compds. of formula I as defined herein, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing a compound of formula I, a method for treatment of a disorder or condition that may be treated by antagonizing histamine H3 receptors, or a method comprising administering to a mammal in need of such treatment, a compound of formula I, for treatment of a disorder or condition selected from the group consisting of depression, mood disorders, schizophrenia, anxiety disorders, Alzheimer's disease, attention-deficit disorder (ADD), attention-deficit hyperactivity disorder (ADHD), psychotic disorders, sleep disorders, obesity, dizziness, epilepsy, motion sickness, respiratory diseases, allergy, allergy-induced airway responses, allergic rhinitis, nasal congestion, allergic congestion, congestion, hypotension, cardiovascular disease, diseases of the GI tract, hyper- and hypomotility and acidic secretion of the gastro-intestinal tract. Compds. of formula I where m and n are independently 1, 2 or 3; Xm and Xn are independently H, F, Cl, Br, I, (F-substituted) C1-6 alkyl, (F-substituted) C1-6 alkoxy, (un)substituted (C1-6alkyl)SOp, where p is 0, 1 or 2; R1 and R2 are independently H, (un)substituted C1-8 alkyl, C3-7 cycloalkyl, C6-14 aryl, (un)substituted 3- to 8-membered heterocycloalkyl, (un)substituted C6-10 arylsulfonyl, or 5- to 10-membered heteroaryl; R3 is (un)substituted C1-8 alkyl, C3-7 cycloalkyl, or C6-14 aryl; or NR1R2 or NR1R3 forms a 4- to 7-membered ring wherein one of the carbons in the ring may be optionally replaced by O, S, NR6, CO, or the ring may be fused to (un)substituted C6-10 arylene, where R6 is H, (un)substituted C1-8 alkyl, 5- to 10-membered (un)substituted (hetero)aryl, or C1-4 alkylcarbonyl; R4 is H or (un)substituted C1-8 alkyl; R5 is H, (F-substituted) C1-6 alkyl, or (F-substituted) C1-6 alkoxy; or pharmaceutically acceptable salts thereof, are claimed in this invention. Example compd. II were prepd. by condensation of 4-bromobenzonitrile with hydroxylamine to give the corresponding N-hydroxyamidine which underwent cyclization with acetic anhydride and the resulting 3-(4-bromophenyl)-5-methyl-[1,2,4]oxadiazole intermediate was coupled with 4-formylphenylboronic acid, to give the oxadiazolylbiphenylcarboxaldehyde, which underwent reductive amination to give example compd. II. An addnl. 71 example compds. were prepd. by this procedure. An assay for detn. of the in vivo affinity of the invention compds. at histamine H3 receptor is described. The percent inhibition of specific binding can be detd. for each dose of the compds., and an IC50 and Ki can be calcd. from these results (no data).

IT 873933-30-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of oxadiazolylbiphenylmethylamines as H3 receptor antagonists for treatment of associated disorders or conditions)
RN 873933-30-3 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[[4'-(5-methyl-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)

L15 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

L15 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1241229 CAPLUS
DOCUMENT NUMBER: 144:6818
TITLE: Indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones as α7 nicotinic receptor agonists, their preparation, pharmaceutical compositions, and use in therapy
INVENTOR(S): Xie, Wenge; Herbert, Brian; Schumacher, Richard A.; Ma, Jianguo; Nguyen, Truc Minh; Gauss, Carla Maria; Tehim, Ashok
PATENT ASSIGNEE(S): Memory Pharmaceuticals Corporation, USA
SOURCE: PCT Int. Appl., 143 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005111038	A2	20051124	WO 2005-US15937	20050506
WO 2005111038	A3	20060831		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005243147	A1	20051124	AU 2005-243147	20050506
CA 2565984	A1	20051124	CA 2005-2565984	20050506
US 2005272735	A1	20051208	US 2005-123219	20050506
EP 1745046	A2	20070124	EP 2005-747486	20050506
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
IN 2006DN06854	A	20070831	IN 2006-DN6854	20061117
NO 2006005622	A	20070202	NO 2006-5622	20061206
KR 2007015607	A	20070205	KR 2006-725685	20061206

PRIORITY APPLN. INFO.: US 2004-568696P P 20040507
US 2004-574712P P 20040527
US 2004-626469P P 20041110
WO 2005-US15937 W 20050506
US 2005-568696P P 20050507

OTHER SOURCE(S): CASREACT 144:6818; MARPAT 144:6818

L15 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
GI


I


II


III


IV


V

AB The invention relates to heteroaryl-substituted azabicyclic compds., e.g., I or II, which are ligands for nicotinic acetylcholine receptors (nAChR) and can be used for the activation of nAChRs and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. In compds. I and II, B is CH2, C=O, or C=S; m is 1 or 2; Y is O or S; X1 to X4 are independently selected from N and (un)substituted C, wherein at most one of X1 to X4 is N; X5 and X6 are independently selected from CH, fluoro-substituted C1-6 alkoxy-C, and heterocyclyl-C, wherein no more than one of X5 and X6 is CH; X7 is CH or N; and R is H, (halo)-C1-4 alkyl, C3-7 cycloalkyl, C4-7 cycloalkylalkyl, and C1-6 alkyl-C6-10 aryl. The invention also relates to the preparation of the heteroaryl-substituted diazabicyclic compds., pharmaceutical compns. comprising those compds. and a pharmaceutically acceptable carrier, as well as to the use of the compns. as agonists for the α7 nAChR subtype. Acylation of 3-methoxythiophenol with oxalyl chloride followed by cyclization gave benzothiophenedione III, which

L15 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
underwent oxidative cleavage resulting in the formation of benzoisothiazolecarboxamide IV. Alk. hydrolysis of IV to the carboxylic acid was followed by coupling with 1,4-diazabicyclo[3.2.2]nonane to give compd. V. The preferred compds. of the invention express binding affinities of 5 nM to 2.5 μM (no data).

IT 869783-40-4P, 3-(1,4-Diazabicyclo[3.2.2]non-4-ylmethyl)-6-(methoxy)-4H-chromen-4-one 869783-41-5P, 3-(1,4-Diazabicyclo[3.2.2]non-4-ylmethyl)-6-(methoxy)-4H-chromen-4-one formate 869783-44-8P, 3-(1,4-Diazabicyclo[3.2.2]non-4-ylmethyl)-5-(methoxy)-4H-chromen-4-one 869783-45-9P, 3-(1,4-Diazabicyclo[3.2.2]non-4-ylmethyl)-5-(methoxy)-4H-chromen-4-one formate 869783-48-2P, 3-(1,4-Diazabicyclo[3.2.2]non-4-ylmethyl)-7-(methoxy)-4H-chromen-4-one 869783-49-3P, 3-(1,4-Diazabicyclo[3.2.2]non-4-ylmethyl)-7-(methoxy)-4H-chromen-4-one formate
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of heteroaryl-substituted diazabicyclo[3.2.2]nonanes as α7 nicotinic receptor agonists)

RN 869783-40-4 CAPLUS
CN 4H-1-Benzopyran-4-one, 3-(1,4-diazabicyclo[3.2.2]non-4-ylmethyl)-6-methoxy- (CA INDEX NAME)



RN 869783-41-5 CAPLUS
CN Formic acid, compd. with 3-(1,4-diazabicyclo[3.2.2]non-4-ylmethyl)-6-methoxy-4H-1-benzopyran-4-one (1:1) (CA INDEX NAME)

CM 1

CRN 869783-40-4
CMF C18 H22 N2 O3



CM 2

CRN 64-18-6
CMF C H2 O2

L15 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 869783-44-8 CAPLUS
CN 4H-1-Benzopyran-4-one, 3-(1,4-diazabicyclo[3.2.2]non-4-ylmethyl)-5-methoxy- (CA INDEX NAME)



RN 869783-45-9 CAPLUS
CN Formic acid, compd. with 3-(1,4-diazabicyclo[3.2.2]non-4-ylmethyl)-5-methoxy-4H-1-benzopyran-4-one (1:1) (CA INDEX NAME)

CM 1

CRN 869783-44-8
CMF C18 H22 N2 O3



CM 2

CRN 64-18-6
CMF C H2 O2

RN 869783-48-2 CAPLUS
CN 4H-1-Benzopyran-4-one, 3-(1,4-diazabicyclo[3.2.2]non-4-ylmethyl)-7-methoxy- (CA INDEX NAME)

L15 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 869783-49-3 CAPLUS
CN Formic acid, compd. with 3-(1,4-diazabicyclo[3.2.2]non-4-ylmethyl)-7-methoxy-4H-1-benzopyran-4-one (1:1) (CA INDEX NAME)

CM 1

CRN 869783-48-2
CMF C18 H22 N2 O3



CM 2

CRN 64-18-6
CMF C H2 O2

L15 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:300453 CAPLUS
DOCUMENT NUMBER: 142:373869
TITLE: A preparation of diazabicyclononane derivatives, useful as nicotinic acetylcholine agonists
INVENTOR(S): Ernst, Glen; Phillips, Elfion; Schmiesing, Richard J.
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Ltd.
SOURCE: PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005030777	A1	20050407	WO 2004-GB4130	20040924
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1673372	A1	20060628	EP 2004-768673	20040924
EP 1673372	B1	20070530		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
JP 2007506723	T	20070322	JP 2006-527492	20040924
AT 363484	T	20070615	AT 2004-768673	20040924
US 2007043031	A1	20070222	US 2006-573132	20061023
PRIORITY APPLN. INFO.:			US 2003-506664P P	20030926
			WO 2004-GB4130 W	20040924

OTHER SOURCE(S): CASREACT 142:373869; MARPAT 142:373869
GI



AB The invention relates to a preparation of diazabicyclononane derivs. of formula
Q-E-D [wherein: Q is diazabicyclononane derivative; E is alk(en/yn)yl,

L15 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
thiazolyl, oxazolyl, or imidazolyl, etc.; D is H, alkyl, Ph, or pyridyl, etc.], useful as nicotinic acetylcholine agonists. For instance, diazabicyclononane deriv. I was prepd. via reductive amination of phenylpropargyl aldehyde by 1,4-diazabicyclo[3.2.2]nonane dihydrochloride.
Biol. investigation included assays for detg. affinity at α7 nAChR and α4 nAChR (Ki values were less than 1000 nM in both tests).
IT 849430-68-8P, (1,4-Diazabicyclo[3.2.2]non-4-yl)(6-bromopyridin-2-yl)methane
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of diazabicyclononane derivs. useful as nicotinic acetylcholine agonists)
RN 849430-68-8 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[(6-bromo-2-pyridinyl)methyl]- (9CI) (CA INDEX NAME)



IT 849430-59-7P 849430-60-0P, (1,4-Diazabicyclo[3.2.2]non-4-yl)(5-phenylfuran-2-yl)methane 849430-61-1P, (1,4-Diazabicyclo[3.2.2]non-4-yl)(biphenyl-4-yl)methane 849430-62-2P, (1,4-Diazabicyclo[3.2.2]non-4-yl)(5-phenylthiophen-2-yl)methane 849430-63-3P, (1,4-Diazabicyclo[3.2.2]non-4-yl)(benzofuran-2-yl)methane 849430-64-4P, (1,4-Diazabicyclo[3.2.2]non-4-yl)(naphthalen-2-yl)methane 849430-65-5P, 3-(1,4-Diazabicyclo[3.2.2]non-4-yl)-1-phenylpropene 849430-66-6P, (1,4-Diazabicyclo[3.2.2]non-4-yl)(benzothiophen-3-yl)methane 849430-67-7P, (1,4-Diazabicyclo[3.2.2]non-4-yl)[4-(2-pyridyl)phenyl]methane 849430-69-9P, (1,4-Diazabicyclo[3.2.2]non-4-yl)(quinolin-3-yl)methane 849430-70-2P, (1,4-Diazabicyclo[3.2.2]non-4-yl)(quinolin-2-yl)methane 849430-71-3P, 4-(4-Phenylthiophen-2-ylmethyl)-1,4-diazabicyclo[3.2.2]nonane 849430-72-4P, 4-[5-(Pyridin-2-yl)thiophen-2-ylmethyl]-1,4-diazabicyclo[3.2.2]nonane 849430-73-5P, 4-(Biphenyl-3-ylmethyl)-1,4-diazabicyclo[3.2.2]nonane 849430-74-6P, 4-(Pyridin-2-ylmethyl)-1,4-diazabicyclo[3.2.2]nonane 849430-76-8P, 4-(6-Phenylpyridin-2-ylmethyl)-1,4-diazabicyclo[3.2.2]nonane 849430-77-9P, 4-(3-Phenylpropyl)-1,4-diazabicyclo[3.2.2]nonane 849430-78-0P, 4-(2-Benzyloxyethyl)-1,4-diazabicyclo[3.2.2]nonane 849430-79-1P, 4-(4-Bromofuran-2-ylmethyl)-1,4-

L15 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
diazabicyclo[3.2.2]nonane 849430-80-4P 849430-81-5P 849430-82-6P 849430-83-7P, (1,4-Diazabicyclo[3.2.2]non-4-yl)[5-(3-pyridyl)thiophen-2-yl]methane 849430-84-8P, (1,4-Diazabicyclo[3.2.2]non-4-yl)[5-(4-pyridyl)thiophen-2-yl]methane 849430-85-9P, (1,4-Diazabicyclo[3.2.2]non-4-yl)[4-(2-pyridyl)thiophen-2-yl]methane 849430-86-0P, (1,4-Diazabicyclo[3.2.2]non-4-yl)[4-(3-pyridyl)thiophen-2-yl]methane 849430-87-1P, (1,4-Diazabicyclo[3.2.2]non-4-yl)[4-(4-pyridyl)thiophen-2-yl]methane 849430-88-2P, (1,4-Diazabicyclo[3.2.2]non-4-yl)(isoquinolin-3-yl)methane 849430-89-3P, (1,4-Diazabicyclo[3.2.2]non-4-yl)(4-phenylpyridin-2-yl)methane 849430-90-6P, (1,4-Diazabicyclo[3.2.2]non-4-yl)(5-phenylpyridin-2-yl)methane 849430-91-7P, 4-(4-Bromothiophen-2-ylmethyl)-1,4-diazabicyclo[3.2.2]nonane 849430-92-8P, 4-(5-Bromothiophen-2-ylmethyl)-1,4-diazabicyclo[3.2.2]nonane 849430-93-9P, 4-[4-(4-Methoxyphenyl)thiophen-2-ylmethyl]-1,4-diazabicyclo[3.2.2]nonane 849430-94-0P, 4-[4-(4-Chlorophenyl)thiophen-2-ylmethyl]-1,4-diazabicyclo[3.2.2]nonane 849430-95-1P, 4-[5-(4-Methoxyphenyl)thiophen-2-ylmethyl]-1,4-diazabicyclo[3.2.2]nonane 849430-96-2P, 4-[5-(4-Chlorophenyl)thiophen-2-ylmethyl]-1,4-diazabicyclo[3.2.2]nonane 849430-97-3P, 4-[5-(3-Chlorophenyl)thiophen-2-ylmethyl]-1,4-diazabicyclo[3.2.2]nonane 849430-98-4P, 4-(Quinoxalin-2-ylmethyl)-1,4-diazabicyclo[3.2.2]nonane 849430-99-5P, 4-(2-Bromothiazol-5-ylmethyl)-1,4-diazabicyclo[3.2.2]nonane 849431-00-1P, 4-(Thiazol-5-ylmethyl)-1,4-diazabicyclo[3.2.2]nonane 849431-01-2P, 4-(2-Phenylthiazol-5-ylmethyl)-1,4-diazabicyclo[3.2.2]nonane 849431-02-3P, 4-(2-Phenylimidazol-5-ylmethyl)-1,4-diazabicyclo[3.2.2]nonane 849431-03-4P, 4-(Thiazol-2-ylmethyl)-1,4-diazabicyclo[3.2.2]nonane 849431-04-5P, 4-(Benzothiazol-2-ylmethyl)-1,4-diazabicyclo[3.2.2]nonane 849431-05-6P, 4-(1-Methylbenzimidazol-2-ylmethyl)-1,4-diazabicyclo[3.2.2]nonane 849431-06-7P, 4-(3-Methyl-5-phenylthiophen-2-ylmethyl)-1,4-diazabicyclo[3.2.2]nonane 849431-07-8P, 4-(2-Phenylthiazol-4-ylmethyl)-1,4-diazabicyclo[3.2.2]nonane 849431-08-9P, 4-[4-(3-Bromophenyl)thiazol-2-ylmethyl]-1,4-diazabicyclo[3.2.2]nonane 849431-09-0P, 4-(4-Phenylthiazol-2-ylmethyl)-1,4-diazabicyclo[3.2.2]nonane 849431-10-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of diazabicyclononane derivs. useful as nicotinic acetylcholine agonists)
RN 849430-59-7 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-(3-phenyl-2-propynyl)- (9CI) (CA INDEX NAME)



L15 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 849430-60-0 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[(5-phenyl-2-furanyl)methyl]- (9CI) (CA INDEX NAME)



RN 849430-61-1 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-([1,1'-biphenyl]-4-ylmethyl)- (9CI) (CA INDEX NAME)



RN 849430-62-2 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[(5-phenyl-2-thienyl)methyl]- (9CI) (CA INDEX NAME)

L15 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 849430-66-6 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-(benzo[b]thien-3-ylmethyl)- (9CI) (CA INDEX NAME)



RN 849430-67-7 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[[4-(2-pyridinyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 849430-69-9 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-(3-quinolinylmethyl)- (9CI) (CA INDEX NAME)



L15 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 849430-63-3 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-(2-benzofuranylmethyl)- (9CI) (CA INDEX NAME)



RN 849430-64-4 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)



RN 849430-65-5 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-(3-phenyl-2-propenyl)- (9CI) (CA INDEX NAME)

L15 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 849430-70-2 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-(2-quinolinylmethyl)- (9CI) (CA INDEX NAME)



RN 849430-71-3 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[(4-phenyl-2-thienyl)methyl]- (9CI) (CA INDEX NAME)



RN 849430-72-4 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[[5-(2-pyridinyl)-2-thienyl]methyl]- (9CI) (CA INDEX NAME)



RN 849430-73-5 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-([1,1'-biphenyl]-3-ylmethyl)- (9CI) (CA

L15 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
INDEX NAME)



RN 849430-74-6 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 849430-76-8 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[(6-phenyl-2-pyridinyl)methyl]- (9CI) (CA INDEX NAME)

L15 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 849430-77-9 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-(3-phenylpropyl)- (9CI) (CA INDEX NAME)



RN 849430-78-0 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[2-(phenylmethoxy)ethyl]- (9CI) (CA INDEX NAME)



RN 849430-79-1 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[(4-bromo-2-furanyl)methyl]- (9CI) (CA INDEX NAME)

L15 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 849430-80-4 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[[4-[(4-bromophenyl)sulfonyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 849430-81-5 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)

L15 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 849430-82-6 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)



RN 849430-83-7 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[[5-(3-pyridinyl)-2-thienyl]methyl]- (9CI) (CA INDEX NAME)

L15 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 849430-84-8 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[[5-(4-pyridinyl)-2-thienyl]methyl]- (9CI) (CA INDEX NAME)



RN 849430-85-9 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[[4-(2-pyridinyl)-2-thienyl]methyl]- (9CI) (CA INDEX NAME)

L15 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 849430-88-2 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-(3-isoquinolinylmethyl)- (9CI) (CA INDEX
NAME)



RN 849430-89-3 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[(4-phenyl-2-pyridinyl)methyl]- (9CI) (CA INDEX NAME)



RN 849430-90-6 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[(5-phenyl-2-pyridinyl)methyl]- (9CI) (CA INDEX NAME)

L15 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 849430-86-0 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[[4-(3-pyridinyl)-2-thienyl]methyl]- (9CI) (CA INDEX NAME)



RN 849430-87-1 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[[4-(4-pyridinyl)-2-thienyl]methyl]- (9CI) (CA INDEX NAME)

L15 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 849430-91-7 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[(4-bromo-2-thienyl)methyl]- (9CI) (CA INDEX NAME)



RN 849430-92-8 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[(5-bromo-2-thienyl)methyl]- (9CI) (CA INDEX NAME)



RN 849430-93-9 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[[4-(4-methoxyphenyl)-2-thienyl]methyl]-

L15 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(9CI) (CA INDEX NAME)



RN 849430-94-0 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[[4-(4-chlorophenyl)-2-thienyl]methyl]-
(9CI) (CA INDEX NAME)



RN 849430-95-1 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[[5-(4-methoxyphenyl)-2-thienyl]methyl]-
(9CI) (CA INDEX NAME)

L15 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 849430-96-2 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[[5-(4-chlorophenyl)-2-thienyl]methyl]-
(9CI) (CA INDEX NAME)



RN 849430-97-3 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[[5-(3-chlorophenyl)-2-thienyl]methyl]-
(9CI) (CA INDEX NAME)

L15 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 849430-98-4 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-(2-quinoxalinylmethyl)- (9CI) (CA INDEX
NAME)



RN 849430-99-5 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[(2-bromo-5-thiazolyl)methyl]- (9CI)
(CA
INDEX NAME)



RN 849431-00-1 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-(5-thiazolylmethyl)- (9CI) (CA INDEX
NAME)

L15 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 849431-01-2 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[(2-phenyl-5-thiazolyl)methyl]- (9CI)
(CA INDEX NAME)



RN 849431-02-3 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[(2-phenyl-1H-imidazol-4-yl)methyl]-
(9CI) (CA INDEX NAME)



RN 849431-03-4 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-(2-thiazolylmethyl)- (9CI) (CA INDEX
NAME)

L15 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 849431-04-5 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-(2-benzothiazolylmethyl)- (9CI) (CA INDEX NAME)



RN 849431-05-6 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[(1-methyl-1H-benzimidazol-2-yl)methyl]- (9CI) (CA INDEX NAME)



RN 849431-06-7 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[(3-methyl-5-phenyl-2-thienyl)methyl]- (9CI) (CA INDEX NAME)

L15 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 849431-09-0 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[(4-phenyl-2-thiazolyl)methyl]- (9CI) (CA INDEX NAME)



RN 849431-10-3 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[(4-[1,1'-biphenyl]-3-yl-2-thiazolyl)methyl]- (9CI) (CA INDEX NAME)

L15 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 849431-07-8 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[(2-phenyl-4-thiazolyl)methyl]- (9CI) (CA INDEX NAME)



RN 849431-08-9 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[[4-(3-bromophenyl)-2-thiazolyl]methyl]- (9CI) (CA INDEX NAME)

L15 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1997:701404 CAPLUS
DOCUMENT NUMBER: 127:355342
TITLE: Aralkyl-bridged diazabicycloalkane derivatives for CNS disorders, and preparation thereof
INVENTOR(S): Bowen, Wayne; De Costa, Brian R.; Dominguez, Celia; He, Xiao-Shu; Rice, Kenner C.
PATENT ASSIGNEE(S): United States Dept. of Health and Human Services, USA
SOURCE: U.S., 13 pp., Cont. of U.S. Ser. No. 950,359, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5679673	A	19971021	US 1994-344304	19941121
PRIORITY APPLN. INFO.:			US 1992-950359	B1 19920924

GI



I

AB Certain aralkyl diazabicycloalkyl compds. are described for treatment of CNS disorders, e.g. cerebral ischemia, psychoses, and convulsions. Compds. of particular interest are I (R, R1, R4, R5, R6, R7 = H, lower alkyl, benzyl, halo-lower alkyl; R2, R3, R10-R13 = H, OH, lower alkyl, benzyl, phenoxy, benzyloxy , halo-lower alkyl; R8, R9 = H, lower alkyl, benzyl and halo-lower alkyl; m = 2-4; A = Ph, naphthyl, benzothiophenyl, benzofuranyl, thienyl; wherein any of the foregoing A groups can be further substituted with ≥1 of H, OH, lower alkyl, lower alkoxy, halo, halo-lower alkyl, amino, mono- and di-lower alkylamino), or a pharmaceutically acceptable salt thereof. Preparation of 4-[2-(3,4-Dichlorophenyl)ethyl]-1,4-diazabicyclo[2.2.3]nonane is described, as is its activity in a sigma receptor assay.
IT 150235-80-6P
RL: BAC (Biological activity or effector, except adverse); BPR (Biological

L15 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L15 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
process); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(aralkyl-bridged diazabicycloalkane derivs. for CNS disorders, and prepn. thereof)
RN 150235-80-6 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[2-(3,4-dichlorophenyl)ethyl]- (9CI) (CA INDEX NAME)



IT 198482-85-8 198482-87-0
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(aralkyl-bridged diazabicycloalkane derivs. for CNS disorders, and preparation thereof)
RN 198482-85-8 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-(2-benzo[b]thien-3-ylethyl)- (9CI) (CA INDEX NAME)



RN 198482-87-0 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[2-(2-naphthalenyl)ethyl]- (9CI) (CA INDEX NAME)

L15 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1995:313069 CAPLUS
DOCUMENT NUMBER: 122:122955
TITLE: Cytotoxic effects of sigma ligands: sigma receptor-mediated alterations in cellular morphology and viability
AUTHOR(S): Vilner, Bertold J.; de Costa, Brian R.; Bowen, Wayne D.
CORPORATE SOURCE: Unit Receptor Biochem. Pharmacology, National Inst. Diabetes Digestive Kidney Diseases, Bethesda, MD, 20892, USA
SOURCE: Journal of Neuroscience (1995), 15(1, Pt. 1), 117-34
CODEN: JNRSDS; ISSN: 0270-6474
PUBLISHER: Society for Neuroscience
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The morphol. effects of several neuroleptics as well as other novel and prototypic sigma ligands were examined by addition to cultures of C6 glioma cells. Sigma ligands caused loss of processes, assumption of spherical shape, and cessation of cell division. The time course and magnitude of this effect were dependent on the concentration of sigma ligand. Continued exposure to sigma compds. ultimately resulted in cell death. However, the morphol. effect was reversible when sigma ligand was removed shortly after rounding. The potency of compds. to produce these effects generally correlated with binding affinity at sigma receptors of C6 glioma cells membranes labeled with [3H](+)-pentazocine. At a concentration of 100 μM, haloperidol, reduced haloperidol, fluphenazine, perphenazine, trifluoperazine, BD737, LR172, BE1008, and SH344 produced significant effects in 3-6 h of exposure. Other compds., such as trifluoperidol, thioridazine, and (-)-butaclamol, produced significant effects by 24 h of exposure. Despite the requirement of micromolar concns. of ligand (some compds. were effective at 30 μm), the effect showed a remarkable specificity for compds. exhibiting sigma receptor binding affinity. Neuroleptics lacking potent sigma affinity [e.g., (-)-sulpiride, (+)-butaclamol, and clozapine] and other compds. that lack significant sigma affinity but that are agonists or antagonists at dopamine, serotonin, adrenergic, glutamate, phencyclidine, GABA, opiate, or muscarinic cholinergic receptors were without effect on cellular morphol. at concns. up to 300 μM over a period of 72 h. Likewise, blockers and activators of Na+, K+, and Ca2+ channels and a monoamine oxidase inhibitor devoid of sigma affinity were without effect. Interestingly, 1,3-di-o-tolylguanidine (DTG), (+)-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine [(+)-3-PPP], (+)-pentazocine, (+)-cyclazocine, and other sigma-active benzomorphans and morphinans appeared inactive in up to 72 h of culture. However, these compds. interacted synergistically with a subeffective dose of BD737 (30 μM) to produce effects usually in 6 h or less. Also, the pH of the culture medium had a profound effect on the activity of sigma compds. Increasing the pH from the normal range of 7.2-7.4 to pH 8.3-8.5 shifted the dose curves (30, 100, 300 μM) for all sigma compds. to the left. Under these conditions, DTG,(+)-3-PPP, and benzomorphans produced effects in 24 h or less. Decreasing the medium pH to 6.5-6.7 markedly reduced the activity of all sigma ligands, producing

L15 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
significant protection from cytotoxic effects. Importantly, compds. that lacked sigma binding affinity showed neither synergism with 30 μM MD737 nor an increase in activity at higher pH. These results confirm the sigma
receptor specificity of this effect. Sigma ligands had similar effects on
other cells of neuronal and non-neuronal origin, including SK-N-SH and SH-SY5Y neuroblastomas, NCB-20 hybridoma, NG 108-15 neuroblastoma-glioma hybrid, COS-7 (kidney), MRS-5 (lung), and PC12 pheochromosome vital role in cell function and may have important implications for neurodegenerative
disorders and neuroleptic treatment.
IT 150235-80-6, BD 1216
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); BIOL (Biological study)
(cytotoxic effects of sigma ligands: sigma receptor-mediated alterations in cellular morphol. and viability)
RN 150235-80-6 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[2-(3,4-dichlorophenyl)ethyl]- (9CI) (CA
INDEX NAME)



L15 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1994:106904 CAPLUS
DOCUMENT NUMBER: 120:106904
TITLE: Synthesis and evaluation of conformationally restricted N-[2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-(1-pyrrolidinyl)ethylamines at σ receptors. 2. Piperazines, bicyclic amines, bridged bicyclic amines,
and miscellaneous compounds
AUTHOR(S): de Costa, Brian R.; He, Xiaoshu; Linders, Joannes T. M.; Dominguez, Celia; Gu, Zi Qiang; Williams, Wanda; Bowen, Wayne
CORPORATE SOURCE: Lab. Med. Chem., Natl. Inst. Diabetes Dig. Kidney Dis., Bethesda, MD, 20892, USA
SOURCE: Journal of Medicinal Chemistry (1993), 36(16), 2311-20
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 120:106904
GI



I

AB As a continuation of an earlier study (J. Med. Chemical 1992, 35, 4334-4343)
the σ-receptor ligand was conformationally restricted in 2-(1-pyrrolidinyl)-N-[2-(3,4-dichlorophenyl)ethyl]-N-methylethylamine (I) by incorporating it into homologous piperazines and homopiperazines, diazabicyclononanes and decanes, bridgehead bicyclooctanes and nonanes as well as other miscellaneous compds. σ-Receptor binding affinities were obtained using [3H](+)-pentazocine in guinea pig brain membranes. Probably the N lone pair orientation found in the piperazines affords the strongest binding interaction. Other N lone pair orientations or compds. representing unlikely staggered conformations of I [as in 4-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[3.2.2]nonane] show very weak σ interaction. Comparison of the binding data of different N-substituted homologs of I with those of the 1-[2-(3,4-

L15 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
dichlorophenyl)ethyl]-4-alkylpiperazines suggests that the 2 N atoms of I are working in opposition to one another in terms of their sensitivity to steric bulk. The high binding affinity of 1,4-diazabicyclo[4.3.0]nonanes suggests that these may approx. the Me and pyrrolidine ring conformations found in I when it is bound to the σ receptor. Binding data suggest that the conformation of I favors strong binding interaction at σ-receptors. σ-Receptor Ki's was 0.55 nM for 1-[2-(3,4-dichlorophenyl)ethyl]-4-n-butylpiperazine. Overall comparison of the results indicate that I is subject to considerable conformational freedom and suggests that the σ receptor is not subject to rigid stereochem. restraints with I. These results corroborate an earlier study
where I was restrained using simple monocyclic heterocycles.
IT 150235-81-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as σ-receptor antagonist)
RN 150235-81-7 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[2-(3,4-dichlorophenyl)ethyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 150235-80-6
CMF C15 H20 Cl2 N2



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



L15 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1991:102068 CAPLUS
DOCUMENT NUMBER: 114:102068
TITLE: Processes and intermediates for preparing 1,4-diazabicyclo[3.2.2]nonane as a bactericide intermediate
INVENTOR(S): Freidmann, Robert C.; Lackey, John W.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: Can. Pat. Appl., 31 pp.
CODEN: CPXXEB
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2001211	A1	19900425	CA 1989-2001211	19891023
US 4895943	A	19900123	US 1988-262542	19881025
PRIORITY APPLN. INFO.:			US 1988-262542 A	19881025

OTHER SOURCE(S): MARPAT 114:102068
GI



I II IV

AB Compds. [I; X = CO, CH2; R = H, (un)substituted benzyl, benzoyl, or naphthoyl; Q = H; W = CH2CH2OH, CH2CO2R1, CH2CH2R2; R1 = C1-4 (halo)alkyl;
R2 = leaving group; WQ can form CH2CH2, with provisos; and II; R ≠ H = (un)substituted benzyl, benzoyl, naphthoyl] were prepared by cyclization
of dicarboxylate esters R1O2CCH2CH(NHCH2CH2NH2)CH2CO2R3 [III; R1, R3 = C1-4 (halo)alkyl] with an alkyl stannate or trialkylaluminum, benzoylation
of the resulting diazepinone (VI; R4 = benzoyl; R5 = CO2R1), reduction of the
product to a hydroxyethyldiazepine analog followed by OH-group activation and ring closure of the latter. Thus, refluxing III (R1 = R3 = Et) (preparation given) 18 h with (n-Bu)3SnSO3CF3 followed by benzoylation gave 78%
IV (R4 = PhCO, R5 = CO2Et). This in THF was refluxed 18 h with LiAlH4, the product (100%) refluxed 1 h with SOCl2 and the chloroethyl derivative (64%) stirred 1 h with 50% aqueous NaOH to give the title base II (R = H) which was converted to its ditosylate salt (51%). The free base was sufficiently pure to be used to prepare (preparation not given) bactericide
binfloxacin.
IT 127783-88-4P

L15 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and hydrogenolysis of)
RN 127783-88-4 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-(phenylmethyl)- (9CI) (CA INDEX NAME)



L15 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1990:423956 CAPLUS
DOCUMENT NUMBER: 113:23956
TITLE: Preparation of diazabicyclononanes as intermediates for antibacterial quinolones
INVENTOR(S): Friedmann, Robert C.; Lackey, John W.; O'Neill, Brian T.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: U.S., 6 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4895943	A	19900123	US 1988-262542	19881025
US 5026845	A	19910625	US 1989-417120	19891004
EP 366301	A2	19900502	EP 1989-310389	19891011
EP 366301	A3	19910731		
EP 366301	B1	19940831		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
IL 92025	A	19941007	IL 1989-92025	19891017
CA 2001211	A1	19900425	CA 1989-2001211	19891023
DK 8905269	A	19900426	DK 1989-5269	19891024
NO 8904230	A	19900426	NO 1989-4230	19891024
NO 172050	B	19930222		
NO 172050	C	19930602		
AU 8943700	A	19900503	AU 1989-43700	19891024
AU 616062	B2	19911017		
HU 54366	A2	19910228	HU 1989-5422	19891024
HU 205116	B	19920330		
ZA 8908047	A	19910626	ZA 1989-8047	19891024
JP 02174769	A	19900706	JP 1989-278301	19891025
JP 06099408	B	19941207		

PRIORITY APPLN. INFO.: US 1988-262542 A3 19881025

OTHER SOURCE(S): CASREACT 113:23956; MARPAT 113:23956
GI

I

AB Bicyclo compds. I [R2 = (substituted) naphthoyl, benzyl, benzoyl, etc.] were prepared Treatment of 4-phenylmethyl-5-(2-hydroxyethyl)-1,4-diazepine with SOCl2, ring closure, hydrogenolysis over Pd(OH)2, and treatment with toluenesulfonic acid, gave 1,4-diazabicyclo[3.2.2]nonane ditosylate salt.

L15 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
IT 127783-88-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of intermediate for quinolone antibacterial)
RN 127783-88-4 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-(phenylmethyl)- (9CI) (CA INDEX NAME)



L15 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1977:155489 CAPLUS
DOCUMENT NUMBER: 86:155489
TITLE: Synthesis and pharmacological study of quinuclidine analogs of sulpiride and bithiodine
AUTHOR(S): Mikhlina, E. E.; Vorob'eva, V. Ya.; Komarova, N. A.; Sharapov, I. M.; Polezhaeva, A. I.; Mashkovskii, M. D.; Yakhontov, L. N.
CORPORATE SOURCE: Vses. Nauchno-Issled. Khim.-Farm. Inst. im. Ordzhonikidze, Moscow, USSR
SOURCE: Khimiko-Farmatsevticheskii Zhurnal (1976), 10(11), 56-60
CODEN: KHFZAN; ISSN: 0023-1134
DOCUMENT TYPE: Journal
LANGUAGE: Russian
GI



I II III

AB (In this abstract R = 5-sulfamoyl-o-anisoyl). Reaction of quinuclidines I (R1 = 2-CH2NH2, 3-XNH2, 4-NH2, X = bond, CH2CH2, OCH2CH2CH2) with ROEt gave 83.4-97% I (R1 = 2-CH2NHR, 3-XNHR, 4-NHR). Similar treatment of II (R1 = H) gave 97% II (R1 = R). III [X = bond, (CH2)3] were preparation similarly in 84-97% yield. Treatment of Et 3-quinuclidinecarboxylate with 2-thienylmagnesium bromide gave 36.7% 3-quinuclidinyldi-2-thienylcarbinol, which was dehydrated to give 69% methylene derivative None of the prepared compds. had antiemetic activity. LD50 were 9.3-415.0 mg/kg (i.v. white mice). In narcotized cats all prepared compds. at 3-10 mg/kg simultaneously increased the arterial pressure. The quinuclidine derivs. did not have favorable antimetic properties when compared to bithiodine nor did they have significant activity on the cholino- and histaminergic systems.
IT 62190-19-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and pharmacol. of)
RN 62190-19-6 CAPLUS
CN Benzamide, 5-(aminosulfonyl)-N-[3-(1,4-diazabicyclo[3.2.2]non-4-yl)propyl]-2-methoxy- (9CI) (CA INDEX NAME)

L15 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



IT 62190-24-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with ethyl sulfamoylanisate)
RN 62190-24-3 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane-4-propanamine (9CI) (CA INDEX NAME)



```
=> log hold
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      50.72     789.03

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -7.02     -35.10

 SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 17:56:35 ON 19 SEP 2007

Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:SSPTAJHM1624

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page for STN Seminar Schedule - N. America
 NEWS  2  JUL 02  LMEDLINE coverage updated
 NEWS  3  JUL 02  SCISEARCH enhanced with complete author names
 NEWS  4  JUL 02  CHEMCATS accession numbers revised
 NEWS  5  JUL 02  CA/CAplus enhanced with utility model patents from China
 NEWS  6  JUL 16  CAplus enhanced with French and German abstracts
 NEWS  7  JUL 18  CA/CAplus patent coverage enhanced
 NEWS  8  JUL 26  USPATFULL/USPAT2 enhanced with IPC reclassification
 NEWS  9  JUL 30  USGENE now available on STN
 NEWS 10  AUG 06  CAS REGISTRY enhanced with new experimental property tags
 NEWS 11  AUG 06  FSTA enhanced with new thesaurus edition
 NEWS 12  AUG 13  CA/CAplus enhanced with additional kind codes for granted
                  patents
 NEWS 13  AUG 20  CA/CAplus enhanced with CAS indexing in pre-1907 records
 NEWS 14  AUG 27  Full-text patent databases enhanced with predefined
                  patent family display formats from INPADOCDB
 NEWS 15  AUG 27  USPATOLD now available on STN
 NEWS 16  AUG 28  CAS REGISTRY enhanced with additional experimental
                  spectral property data
 NEWS 17  SEP 07  STN AnaVist, Version 2.0, now available with Derwent
                  World Patents Index
 NEWS 18  SEP 13  FORIS renamed to SOFIS
 NEWS 19  SEP 13  INPADOCDB enhanced with monthly SDI frequency
 NEWS 20  SEP 17  CA/CAplus enhanced with printed CA page images from
                  1967-1998
 NEWS 21  SEP 17  CAplus coverage extended to include traditional medicine
                  patents
```

```
 NEWS 22  SEP 24  EMBASE, EMBAL, and LEMBASE reloaded with enhancements
 NEWS 23  OCT 02  CA/CAplus enhanced with pre-1907 records from Chemisches
                  Zentralblatt
 NEWS 24  OCT 19  BEILSTEIN updated with new compounds
 NEWS 25  NOV 15  Derwent Indian patent publication number format enhanced

 NEWS EXPRESS  19 SEPTEMBER 2007:  CURRENT WINDOWS VERSION IS V8.2,
               CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:37:40 ON 15 NOV 2007

=> file registry
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'REGISTRY' ENTERED AT 10:38:17 ON 15 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   14 NOV 2007  HIGHEST RN 953817-57-7
DICTIONARY FILE UPDATES:  14 NOV 2007  HIGHEST RN 953817-57-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:
```

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10 series\10573132\10573132c.str





chain nodes :
10 11
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
7-10 10-11
ring bonds :
1-2 1-7 2-3 3-4 3-8 4-5 5-6 6-7 6-9 8-9
exact/norm bonds :
1-2 1-7 2-3 3-4 3-8 4-5 5-6 6-7 6-9 8-9 10-11
exact bonds :
7-10

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:Atom

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 10:38:33 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     3834 TO ITERATE

 52.2% PROCESSED     2000 ITERATIONS                                 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        72967 TO    80393
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 10:38:37 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    77369 TO ITERATE

100.0% PROCESSED    77369 ITERATIONS                               46 ANSWERS
SEARCH TIME: 00.00.04

L3           46 SEA SSS FUL L1

=> d scan
```

L3 46 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1,4-Diazabicyclo[3.2.2]nonane, 4-[[4-(2-pyridinyl)-2-thienyl]methyl]-
MF C17 H21 N3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3

L3 46 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1,4-Diazabicyclo[3.2.2]nonane, 4-[[4-(4-chlorophenyl)-2-thienyl]methyl]-
MF C18 H21 Cl N2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 46 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1,4-Diazabicyclo[3.2.2]nonane, 4-(2-thiazolylmethyl)-
MF C11 H17 N3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 46 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Formic acid, compd. with 3-(1,4-diazabicyclo[3.2.2]non-4-ylmethyl)-6-methoxy-4H-1-benzopyran-4-one (1:1)
MF C18 H22 N2 O3 . C H2 O2

CM 1



CM 2

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

```
=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   172.10     172.31

FILE 'CAPLUS' ENTERED AT 10:39:05 ON 15 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 15 Nov 2007  VOL 147 ISS 21
FILE LAST UPDATED: 14 Nov 2007  (20071114/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=>

=> s l3
L4            2 L3

=> d l4 1-2 ibib abs hitstr
```

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1241229 CAPLUS
DOCUMENT NUMBER: 144:6818
TITLE: Indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones as α7 nicotinic receptor agonists, their preparation, pharmaceutical compositions, and use in therapy
INVENTOR(S): Xie, Wenge; Herbert, Brian; Schumacher, Richard A.; Ma, Jianguo; Nguyen, Truc Minh; Gauss, Carla Maria; Tehim, Ashok
PATENT ASSIGNEE(S): Memory Pharmaceuticals Corporation, USA
SOURCE: PCT Int. Appl., 143 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005111038	A2	20051124	WO 2005-US15937	20050506
WO 2005111038	A3	20060831		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005243147	A1	20051124	AU 2005-243147	20050506
CA 2565984	A1	20051124	CA 2005-2565984	20050506
US 2005272735	A1	20051208	US 2005-123219	20050506
EP 1745046	A2	20070124	EP 2005-747486	20050506
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
BR 2005010212	A	20071016	BR 2005-10212	20050506
IN 2006DN06854	A	20070831	IN 2006-DN6854	20061117
NO 2006005622	A	20070202	NO 2006-5622	20061206
KR 2007015607	A	20070205	KR 2006-725685	20061206

PRIORITY APPLN. INFO.: US 2004-568696P P 20040507
US 2004-574712P P 20040527
US 2004-626469P P 20041110
WO 2005-US15937 W 20050506
US 2005-568696P P 20050507

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

OTHER SOURCE(S): CASREACT 144:6818; MARPAT 144:6818
GI


I


II


III


IV


V

AB The invention relates to heteroaryl-substituted azabicyclic compds., e.g., I or II, which are ligands for nicotinic acetylcholine receptors (nAChR) and can be used for the activation of nAChRs and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. In compds. I and II, B is CH2, C=O, or C=S; m is 1 or 2; Y is O or S; X1 to X4 are independently selected from N and (un)substituted C, wherein at most one of X1 to X4 is N; X5 and X6 are independently selected from CH, fluoro-substituted C1-6 alkoxy-C, and heterocyclyl-C, wherein no more than one of X5 and X6 is CH; X7 is CH or N; and R is H, (halo)-C1-4 alkyl, C3-7 cycloalkyl, C4-7 cycloalkylalkyl, and C1-6 alkyl-C6-10 aryl. The invention also relates to the preparation of the heteroaryl-substituted diazabicyclic compds., pharmaceutical compns. comprising those compds. and a pharmaceutically acceptable carrier, as well as to the use of the compns. as agonists for the α7 nAChR subtype. Acylation of 3-methoxythiophenol with oxalyl

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

chloride followed by cyclization gave benzothiophenedione III, which underwent oxidative cleavage resulting in the formation of benzoisothiazolecarboxamide IV. Alk. hydrolysis of IV to the carboxylic acid was followed by coupling with 1,4-diazabicyclo[3.2.2]nonane to give compd. V. The preferred compds. of the invention express binding affinities of 5 nM to 2.5 μM (no data).

IT 869783-40-4P, 3-(1,4-Diazabicyclo[3.2.2]non-4-ylmethyl)-6-(methoxy)-4H-chromen-4-one 869783-41-5P, 3-(1,4-Diazabicyclo[3.2.2]non-4-ylmethyl)-6-(methoxy)-4H-chromen-4-one formate 869783-44-8P, 3-(1,4-Diazabicyclo[3.2.2]non-4-ylmethyl)-5-(methoxy)-4H-chromen-4-one 869783-45-9P, 3-(1,4-Diazabicyclo[3.2.2]non-4-ylmethyl)-5-(methoxy)-4H-chromen-4-one formate 869783-48-2P, 3-(1,4-Diazabicyclo[3.2.2]non-4-ylmethyl)-7-(methoxy)-4H-chromen-4-one 869783-49-3P, 3-(1,4-Diazabicyclo[3.2.2]non-4-ylmethyl)-7-(methoxy)-4H-chromen-4-one formate
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of heteroaryl-substituted diazabicyclo[3.2.2]nonanes as α7 nicotinic receptor agonists)

RN 869783-40-4 CAPLUS
CN 4H-1-Benzopyran-4-one, 3-(1,4-diazabicyclo[3.2.2]non-4-ylmethyl)-6-methoxy- (CA INDEX NAME)



RN 869783-41-5 CAPLUS
CN Formic acid, compd. with 3-(1,4-diazabicyclo[3.2.2]non-4-ylmethyl)-6-methoxy-4H-1-benzopyran-4-one (1:1) (CA INDEX NAME)

CM 1

CRN 869783-40-4
CMF C18 H22 N2 O3



CM 2

CRN 64-18-6

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CMF C H2 O2



RN 869783-44-8 CAPLUS
CN 4H-1-Benzopyran-4-one, 3-(1,4-diazabicyclo[3.2.2]non-4-ylmethyl)-5-methoxy- (CA INDEX NAME)



RN 869783-45-9 CAPLUS
CN Formic acid, compd. with 3-(1,4-diazabicyclo[3.2.2]non-4-ylmethyl)-5-methoxy-4H-1-benzopyran-4-one (1:1) (CA INDEX NAME)

CM 1

CRN 869783-44-8
CMF C18 H22 N2 O3



CM 2

CRN 64-18-6
CMF C H2 O2

RN 869783-48-2 CAPLUS
CN 4H-1-Benzopyran-4-one, 3-(1,4-diazabicyclo[3.2.2]non-4-ylmethyl)-7-methoxy- (CA INDEX NAME)

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 869783-49-3 CAPLUS
CN Formic acid, compd. with 3-(1,4-diazabicyclo[3.2.2]non-4-ylmethyl)-7-methoxy-4H-1-benzopyran-4-one (1:1) (CA INDEX NAME)

CM 1

CRN 869783-48-2
CMF C18 H22 N2 O3



CM 2

CRN 64-18-6
CMF C H2 O2

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:300453 CAPLUS
DOCUMENT NUMBER: 142:373869
TITLE: A preparation of diazabicyclononane derivatives, useful as nicotinic acetylcholine agonists
INVENTOR(S): Ernst, Glen; Phillips, Elfion; Schmiesing, Richard J.
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Ltd.
SOURCE: PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005030777	A1	20050407	WO 2004-GB4130	20040924
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1673372	A1	20060628	EP 2004-768673	20040924
EP 1673372	B1	20070530		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
JP 2007506723	T	20070322	JP 2006-527492	20040924
AT 363484	T	20070615	AT 2004-768673	20040924
US 2007043031	A1	20070222	US 2006-573132	20061023
PRIORITY APPLN. INFO.:			US 2003-506664P	P 20030926
			WO 2004-GB4130	W 20040924

OTHER SOURCE(S): CASREACT 142:373869; MARPAT 142:373869
GI



AB The invention relates to a preparation of diazabicyclononane derivs. of formula
Q-E-D [wherein: Q is diazabicyclononane derivative; E is alk(en/yn)yl,

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
thiazolyl, oxazolyl, or imidazolyl, etc.; D is H, alkyl, Ph, or pyridyl, etc.], useful as nicotinic acetylcholine agonists. For instance, diazabicyclononane deriv. I was prepd. via reductive amination of phenylpropargyl aldehyde by 1,4-diazabicyclo[3.2.2]nonane dihydrochloride.
Biol. investigation included assays for detg. affinity at α7 nAChR and α4 nAChR (Ki values were less than 1000 nM in both tests).
IT 849430-68-8P, (1,4-Diazabicyclo[3.2.2]non-4-yl)(6-bromopyridin-2-yl)methane
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of diazabicyclononane derivs. useful as nicotinic acetylcholine agonists)
RN 849430-68-8 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[(6-bromo-2-pyridinyl)methyl]- (CA INDEX NAME)



IT 849430-60-0P, (1,4-Diazabicyclo[3.2.2]non-4-yl)(5-phenylfuran-2-yl)methane 849430-62-2P, (1,4-Diazabicyclo[3.2.2]non-4-yl)(5-phenylthiophen-2-yl)methane 849430-63-3P, (1,4-Diazabicyclo[3.2.2]non-4-yl)(benzofuran-2-yl)methane 849430-66-6P, (1,4-Diazabicyclo[3.2.2]non-4-yl)(benzothiophen-3-yl)methane 849430-69-9P, (1,4-Diazabicyclo[3.2.2]non-4-yl)(quinolin-3-yl)methane 849430-70-2P, (1,4-Diazabicyclo[3.2.2]non-4-yl)(quinolin-2-yl)methane 849430-71-3P, 4-(4-Phenylthiophen-2-ylmethyl)-1,4-diazabicyclo[3.2.2]nonane 849430-72-4P, 4-[5-(Pyridin-2-yl)thiophen-2-ylmethyl]-1,4-diazabicyclo[3.2.2]nonane 849430-74-6P, 4-(Pyridin-2-ylmethyl)-1,4-diazabicyclo[3.2.2]nonane 849430-76-8P, 4-(6-Phenylpyridin-2-ylmethyl)-1,4-diazabicyclo[3.2.2]nonane 849430-79-1P, 4-(4-Bromofuran-2-ylmethyl)-1,4-diazabicyclo[3.2.2]nonane 849430-83-7P, (1,4-Diazabicyclo[3.2.2]non-4-yl)[5-(3-pyridyl)thiophen-2-yl]methane 849430-84-8P, (1,4-Diazabicyclo[3.2.2]non-4-yl)[5-(4-pyridyl)thiophen-2-yl]methane 849430-85-9P, (1,4-Diazabicyclo[3.2.2]non-4-yl)[4-(2-pyridyl)thiophen-2-yl]methane 849430-86-0P, (1,4-Diazabicyclo[3.2.2]non-4-yl)[4-(3-pyridyl)thiophen-2-yl]methane 849430-87-1P, (1,4-Diazabicyclo[3.2.2]non-4-yl)[4-(4-pyridyl)thiophen-2-yl]methane 849430-88-2P, (1,4-Diazabicyclo[3.2.2]non-4-yl)(isoquinolin-3-

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
yl)methane 849430-89-3P, (1,4-Diazabicyclo[3.2.2]non-4-yl)(4-phenylpyridin-2-yl)methane 849430-90-6P, (1,4-Diazabicyclo[3.2.2]non-4-yl)(5-phenylpyridin-2-yl)methane 849430-91-7P, 4-(4-Bromothiophen-2-ylmethyl)-1,4-diazabicyclo[3.2.2]nonane 849430-92-8P, 4-(5-Bromothiophen-2-ylmethyl)-1,4-diazabicyclo[3.2.2]nonane 849430-93-9P, 4-[4-(4-Methoxyphenyl)thiophen-2-ylmethyl]-1,4-diazabicyclo[3.2.2]nonane 849430-94-0P, 4-[4-(4-Chlorophenyl)thiophen-2-ylmethyl]-1,4-diazabicyclo[3.2.2]nonane 849430-95-1P, 4-[5-(4-Methoxyphenyl)thiophen-2-ylmethyl]-1,4-diazabicyclo[3.2.2]nonane 849430-96-2P, 4-[5-(4-Chlorophenyl)thiophen-2-ylmethyl]-1,4-diazabicyclo[3.2.2]nonane 849430-97-3P, 4-[5-(3-Chlorophenyl)thiophen-2-ylmethyl]-1,4-diazabicyclo[3.2.2]nonane 849430-98-4P, 4-(Quinoxalin-2-ylmethyl)-1,4-diazabicyclo[3.2.2]nonane 849430-99-5P, 4-(2-Bromothiazol-5-ylmethyl)-1,4-diazabicyclo[3.2.2]nonane 849431-00-1P, 4-(Thiazol-5-ylmethyl)-1,4-diazabicyclo[3.2.2]nonane 849431-01-2P, 4-(2-Phenylthiazol-5-ylmethyl)-1,4-diazabicyclo[3.2.2]nonane 849431-02-3P, 4-(2-Phenylimidazol-5-ylmethyl)-1,4-diazabicyclo[3.2.2]nonane 849431-03-4P, 4-(Thiazol-2-ylmethyl)-1,4-diazabicyclo[3.2.2]nonane 849431-04-5P, 4-(Benzothiazol-2-ylmethyl)-1,4-diazabicyclo[3.2.2]nonane 849431-05-6P, 4-(1-Methylbenzimidazol-2-ylmethyl)-1,4-diazabicyclo[3.2.2]nonane 849431-06-7P, 4-(3-Methyl-5-phenylthiophen-2-ylmethyl)-1,4-diazabicyclo[3.2.2]nonane 849431-07-8P, 4-(2-Phenylthiazol-4-ylmethyl)-1,4-diazabicyclo[3.2.2]nonane 849431-08-9P, 4-[4-(3-Bromophenyl)thiazol-2-ylmethyl]-1,4-diazabicyclo[3.2.2]nonane 849431-09-0P, 4-(4-Phenylthiazol-2-ylmethyl)-1,4-diazabicyclo[3.2.2]nonane 849431-10-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of diazabicyclononane derivs. useful as nicotinic acetylcholine agonists)
RN 849430-60-0 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[(5-phenyl-2-furanyl)methyl]- (CA INDEX NAME)



RN 849430-62-2 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[(5-phenyl-2-thienyl)methyl]- (CA INDEX NAME)

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 849430-63-3 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-(2-benzofuranylmethyl)- (CA INDEX NAME)



RN 849430-66-6 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-(benzo[b]thien-3-ylmethyl)- (CA INDEX NAME)



RN 849430-69-9 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-(3-quinolinylmethyl)- (CA INDEX NAME)



RN 849430-70-2 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-(2-quinolinylmethyl)- (CA INDEX NAME)

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 849430-71-3 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[(4-phenyl-2-thienyl)methyl]- (CA INDEX NAME)



RN 849430-72-4 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[[5-(2-pyridinyl)-2-thienyl]methyl]- (CA INDEX NAME)



L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 849430-74-6 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-(2-pyridinylmethyl)- (CA INDEX NAME)



RN 849430-76-8 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[(6-phenyl-2-pyridinyl)methyl]- (CA INDEX NAME)



RN 849430-79-1 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[(4-bromo-2-furanyl)methyl]- (CA INDEX NAME)



L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 849430-83-7 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[[5-(3-pyridinyl)-2-thienyl]methyl]- (CA INDEX NAME)



RN 849430-84-8 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[[5-(4-pyridinyl)-2-thienyl]methyl]- (CA INDEX NAME)



RN 849430-85-9 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[[4-(2-pyridinyl)-2-thienyl]methyl]- (CA INDEX NAME)

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 849430-86-0 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[[4-(3-pyridinyl)-2-thienyl]methyl]- (CA
INDEX NAME)



RN 849430-87-1 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[[4-(4-pyridinyl)-2-thienyl]methyl]- (CA
INDEX NAME)

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
INDEX NAME)



RN 849430-91-7 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[(4-bromo-2-thienyl)methyl]- (CA INDEX
NAME)



RN 849430-92-8 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[(5-bromo-2-thienyl)methyl]- (CA INDEX
NAME)



L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 849430-88-2 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-(3-isoquinolinylmethyl)- (CA INDEX
NAME)



RN 849430-89-3 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[(4-phenyl-2-pyridinyl)methyl]- (CA
INDEX NAME)



RN 849430-90-6 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[(5-phenyl-2-pyridinyl)methyl]- (CA

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 849430-93-9 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[[4-(4-methoxyphenyl)-2-thienyl]methyl]-
(CA INDEX NAME)



RN 849430-94-0 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[[4-(4-chlorophenyl)-2-thienyl]methyl]-
(CA INDEX NAME)



RN 849430-95-1 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[[5-(4-methoxyphenyl)-2-thienyl]methyl]-
(CA INDEX NAME)

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 849430-96-2 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[[5-(4-chlorophenyl)-2-thienyl]methyl]- (CA INDEX NAME)



RN 849430-97-3 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[[5-(3-chlorophenyl)-2-thienyl]methyl]- (CA INDEX NAME)

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 849430-98-4 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-(2-quinoxalinylmethyl)- (CA INDEX NAME)



RN 849430-99-5 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[(2-bromo-5-thiazolyl)methyl]- (CA INDEX NAME)



RN 849431-00-1 CAPLUS

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-(5-thiazolylmethyl)- (CA INDEX NAME)



RN 849431-01-2 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[(2-phenyl-5-thiazolyl)methyl]- (CA INDEX NAME)



RN 849431-02-3 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[(2-phenyl-1H-imidazol-4-yl)methyl]- (9CI) (CA INDEX NAME)



RN 849431-03-4 CAPLUS

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-(2-thiazolylmethyl)- (CA INDEX NAME)



RN 849431-04-5 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-(2-benzothiazolylmethyl)- (CA INDEX NAME)



RN 849431-05-6 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[(1-methyl-1H-benzimidazol-2-yl)methyl]- (CA INDEX NAME)



RN 849431-06-7 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[(3-methyl-5-phenyl-2-thienyl)methyl]- (CA INDEX NAME)

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 849431-07-8 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[(2-phenyl-4-thiazolyl)methyl]- (CA INDEX NAME)



RN 849431-08-9 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[[4-(3-bromophenyl)-2-thiazolyl]methyl]- (CA INDEX NAME)

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 849431-09-0 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[(4-phenyl-2-thiazolyl)methyl]- (CA INDEX NAME)



RN 849431-10-3 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[(4-[1,1'-biphenyl]-3-yl-2-thiazolyl)methyl]- (CA INDEX NAME)

10573132.trn

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	22.76	195.07

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.56	-1.56

STN INTERNATIONAL LOGOFF AT 10:54:35 ON 15 NOV 2007